智通财经APP讯，百奥泰(688177.SH)披露2025年度业绩快报，2025年度实现营业收入9.34亿元，同比增 长25.64%;归属于母公司所有者的净利润亏损3.36亿元，上年同期亏损5.1亿元。 业绩变动主要原因是公司营业收入持续增长：一方面公司积极拓展市场，阿达木单抗注射液(格乐立®) 和托珠单抗注射液(施瑞立®)销售额较上年同期稳步提升;另一方面本报告期公司乌司奴单抗注射液 (STARJEMZA®)于美国上市销售，授权许可收入及销售收入增长。 ...

本报告期公司业绩较上年同期将实现减亏。主要原因是公司营业收入为9亿元到9.7亿元，较上年同期增 加1.57亿元至2.27亿元。一方面公司积极拓展市场，阿达木单抗注射液(格乐立®)和托珠单抗注射液(施 瑞立®)销售额较上年同期稳步提升；另一方面本报告期公司乌司奴单抗注射液(STARJEMZA®)于美国 上市销售，授权许可收入及销售收入增长。 预计归属于母公司所有者扣除非经常性损益后的净利润为-3.8亿元到-4.9亿元，将减少亏损6561.09万元 至1.76亿元。 格隆汇1月27日丨百奥泰(688177.SH)公布，经财务部门初步测算，公司预计2025年度实现归属于母公司 所有者的净利润与上年同期相比，将减少亏损，实现归属于母公司所有者的净利润为-2.8亿元到-3.9亿 元，减少亏损1.20亿元到2.30亿元。 ...

Core Viewpoint - The company Baiotai (688177.SH) expects to reduce its losses in 2025 compared to the previous year, with projected net profit attributable to shareholders ranging from -280 million to -390 million yuan, a reduction in losses by 120 million to 230 million yuan [1] Financial Performance - The company anticipates a net profit attributable to shareholders, excluding non-recurring gains and losses, to be between -380 million and -490 million yuan, reducing losses by 65.61 million to 176 million yuan [1] - The expected operating revenue for the reporting period is between 900 million and 970 million yuan, an increase of 157 million to 227 million yuan compared to the same period last year [1] Market Expansion - The sales of Adalimumab injection (Geleli®) and Tocilizumab injection (Shiruili®) have steadily increased compared to the same period last year, contributing to the company's revenue growth [1] - The company has launched Ustinumab injection (STARJEMZA®) in the U.S., leading to growth in both licensing income and sales revenue [1]